Citation 9616

YOKOZAWA,T: DONG,E: LIU,ZW: SHIMIZU,M:. (1997). ANTIOXIDATIVE ACTIVITY OF FLAVONES AND FLAVONOLS IN VITRO.. 11(6)

Citation Details

Title	ANTIOXIDATIVE ACTIVITY OF FLAVONES AND FLAVONOLS IN VITRO.
Authors	YOKOZAWA,T: DONG,E: LIU,ZW: SHIMIZU,M:
Year	1997
Volume	11
Issue	6

Summary

Year: 1997

Journal: Unknown

Organisms and Their Experiments (1)

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ACETYL CO-A CARBOXYLASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	SORBARIN	ACTIVE
2	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	SORBARIN	ACTIVE
3	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	SORBARIN	ACTIVE
4	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	LUTEOLIN	ACTIVE
5	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	LUTEOLIN	ACTIVE
6	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	LUTEOLIN	ACTIVE
7	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CIRSIMARIN	INACTIVE
8	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CIRSIMARIN	ACTIVE
9	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CIRSIMARIN	ACTIVE
10	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BAICALIN	WEAK ACTIVITY
11	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BAICALIN	ACTIVE
12	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BAICALIN	ACTIVE
13	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	LUTEOLIN,6-HYDROXY:	INACTIVE
14	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	LUTEOLIN,6-HYDROXY:	WEAK ACTIVITY
15	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	LUTEOLIN,6-HYDROXY:	ACTIVE
16	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BAICALEIN	INACTIVE
17	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BAICALEIN	WEAK ACTIVITY
18	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BAICALEIN	ACTIVE
19	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CYNAROSIDE	INACTIVE
20	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CYNAROSIDE	INACTIVE
21	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CYNAROSIDE	WEAK ACTIVITY
22	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	SCUTELLAREIN	ACTIVE
23	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	SCUTELLAREIN	INACTIVE
24	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	SCUTELLAREIN	INACTIVE
25	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	APIGENIN	ACTIVE
26	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	APIGENIN	INACTIVE
27	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	APIGENIN	INACTIVE
28	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TORINGINCIRSILIOLPECTOLINARINACACETINGENKWANINCHRYSOERIOLPLANTAGININCIRSIMARITINCIRSILINEOLLINARINCOSMOSIINAPIINPECTOLINARIGENINRHOIFOLINTECTOCHRYSIN	INACTIVE
29	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TORINGINCIRSILIOLPECTOLINARINACACETINGENKWANINCHRYSOERIOLPLANTAGININCIRSIMARITINCIRSILINEOLLINARINCOSMOSIINAPIINPECTOLINARIGENINRHOIFOLINTECTOCHRYSIN	INACTIVE
30	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TORINGINCIRSILIOLPECTOLINARINACACETINGENKWANINCHRYSOERIOLPLANTAGININCIRSIMARITINCIRSILINEOLLINARINCOSMOSIINAPIINPECTOLINARIGENINRHOIFOLINTECTOCHRYSIN	INACTIVE
31	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RHAMNETIN	ACTIVE
32	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RHAMNETIN	ACTIVE
33	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RHAMNETIN	ACTIVE
34	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HYPEROSIDE	ACTIVE
35	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HYPEROSIDE	ACTIVE
36	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HYPEROSIDE	ACTIVE
37	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	AYANIN A,OXY:	ACTIVE
38	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	AYANIN A,OXY:	ACTIVE
39	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	AYANIN A,OXY:	ACTIVE
40	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCETIN	ACTIVE
41	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCETIN	ACTIVE
42	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCETIN	ACTIVE
43	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CHRYSOSPLENOL B	ACTIVE
44	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CHRYSOSPLENOL B	ACTIVE
45	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CHRYSOSPLENOL B	ACTIVE
46	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAEMPFEROL	ACTIVE
47	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAEMPFEROL	ACTIVE
48	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAEMPFEROL	ACTIVE
49	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCITRIN,ISO:	INACTIVE
50	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCITRIN,ISO:	ACTIVE
51	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCITRIN,ISO:	ACTIVE
52	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CHRYSOSPLENOL C	INACTIVE
53	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CHRYSOSPLENOL C	INACTIVE
54	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CHRYSOSPLENOL C	ACTIVE
55	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCITRIN	ACTIVE
56	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCITRIN	INACTIVE
57	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCITRIN	ACTIVE
58	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCETIN,TETRAMETHYL:	ACTIVE
59	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCETIN,TETRAMETHYL:	ACTIVE
60	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCETIN,TETRAMETHYL:	ACTIVE
61	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCIMERITRIN	WEAK ACTIVITY
62	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCIMERITRIN	INACTIVE
63	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	QUERCIMERITRIN	ACTIVE
64	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RUTIN	ACTIVE
65	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RUTIN	INACTIVE
66	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RUTIN	INACTIVE
67	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAEMPFEROL-7-GLUCOSIDERHAMNETIN,ISO:KAEMPFERITRINCHRYSOSPLENOL DAFZELIN	INACTIVE
68	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAEMPFEROL-7-GLUCOSIDERHAMNETIN,ISO:KAEMPFERITRINCHRYSOSPLENOL DAFZELIN	INACTIVE
69	LIPID PEROXIDE FORMATION INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	KAEMPFEROL-7-GLUCOSIDERHAMNETIN,ISO:KAEMPFERITRINCHRYSOSPLENOL DAFZELIN	INACTIVE

Citation 9616

Citation Details

Summary

Organisms and Their Experiments (1)

Unknown organism

Show SPARQL Queries (1)

Query 1